Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $0.108
America/New_York / 23 jan 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 5.95 mill |
EPS: | -5.29 |
P/E: | -0.0204 |
Earnings Date: | Mar 27, 2023 |
SharesOutstanding: | 55.11 mill |
Avg Daily Volume: | 12.58 mill |
RATING 2023-03-27 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Buy | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0204 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.0204 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.0260 - 0.190 ( +/- 75.93%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-22 | Orbimed Advisors Llc | Sell | 1 034 421 | Common Stock |
2022-11-23 | Orbimed Advisors Llc | Sell | 5 617 300 | Common Stock |
2022-11-25 | Orbimed Advisors Llc | Sell | 3 629 226 | Common Stock |
2022-11-22 | Bonita David P | Sell | 1 034 421 | Common Stock |
2022-11-23 | Bonita David P | Sell | 5 617 300 | Common Stock |
INSIDER POWER |
---|
-75.78 |
Last 100 transactions |
Buy: 5 461 904 | Sell: 28 520 680 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.108 (0.00% ) |
Volume | 31.13 mill |
Avg. Vol. | 12.58 mill |
% of Avg. Vol | 247.50 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.